Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Pharmacokinetic Analysis of Subcutaneous Levodopa/Carbidopa Delivery With ND0612
Objective: To (i) use a population pharmacokinetic (PK) model to compare predicted levodopa PK parameters when levodopa is delivered as investigational ND0612, as oral immediate-release…A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations
Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…Utilizing the Levodopa Challenge Test to Clarify Clinical Complaints Following Levodopa Administration: A Case Series
Objective: To characterize subjective clinical complaints reported by patients with Parkinson's Disease (PD) following levodopa administration and evaluate the utility of the levodopa challenge test…Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose
Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…The efficacy and safety of continuous subcutaneous infusion therapy with foslevodopa/foscarbidopa
Objective: To clarify the actual status of CSCI therapy, cases in which CSCI therapy was started at our hospital were investigated. Background: Continuous subcutaneous infusion…Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial
Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Levodopa response in pathology-confirmed Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy
Objective: to describe the rate of levodopa response, phenotypical characteristics, prognostic implications and pathological features in a large cohort of patients with pathology-confirmed Parkinson’s disease…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 62
- Next Page »